Cuban-U.S. Research Collaborations Easier Now

President Obama’s executive actions remove some of the red tape for American and Cuban scientists to work together.

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

FLICKR, DIDIER BAERTSCHIGERBeginning this week (October 17), US-based researchers will find it easier to collaborate with Cuban counterparts on medical projects, thanks to executive actions issued by President Barack Obama. Among other provisions, the new rules also allow for Cuban drug developers to seek approval from the US Food and Drug Administration to sell medications in the U.S.

“These changes are intended to expand opportunities for scientific collaboration by authorizing certain transactions related to Cuban-origin pharmaceuticals and joint medical research,” according to a press release from the US Department of the Treasury. The Department’s Office of Foreign Assets Control and the Department of Commerce’s Bureau of Industry and Security “are making these amendments in support of the process of normalizing bilateral relations with Cuba.”

According to ScienceInsider, Cuban researchers could receive US federal funds for research endeavors. “If it’s truly feasible to use federal grants to support Cuban research, then everybody wins,” immunologist Thomas Schwaab, the chief of strategy, business development, and outreach at Roswell Park Cancer Institute in Buffalo, New York, told ScienceInsider. “Cuban science has taken a completely novel approach to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies